These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30867522)

  • 41. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials.
    Birrer DL; Golcher H; Casadei R; Haile SR; Fritsch R; Hussung S; Brunner TB; Fietkau R; Meyer T; Grützmann R; Merkel S; Ricci C; Ingaldi C; Di Marco M; Guido A; Serra C; Minni F; Pestalozzi B; Petrowsky H; DeOliveira M; Bechstein WO; Bruns CJ; Oberkofler CE; Puhan M; Lesurtel M; Heinrich S; Clavien PA
    Ann Surg; 2021 Nov; 274(5):713-720. PubMed ID: 34334656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis.
    Mollberg N; Rahbari NN; Koch M; Hartwig W; Hoeger Y; Büchler MW; Weitz J
    Ann Surg; 2011 Dec; 254(6):882-93. PubMed ID: 22064622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
    Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
    HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Int J Surg; 2018 Apr; 52():221-228. PubMed ID: 29425826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
    Ghanem I; Lora D; Herradón N; de Velasco G; Carretero-González A; Jiménez-Varas MÁ; Vázquez de Parga P; Feliu J
    ESMO Open; 2022 Jun; 7(3):100485. PubMed ID: 35580504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis.
    Xue K; Huang X; Zhao P; Zhang Y; Tian B
    Int J Surg; 2023 Dec; 109(12):4309-4321. PubMed ID: 38259002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Esophageal Cancer Patients: A Systematic Review and Meta-Analysis.
    Xiao X; Hong HG; Zeng X; Yang YS; Luan SY; Li Y; Chen LQ; Yuan Y
    World J Surg; 2020 Dec; 44(12):4161-4174. PubMed ID: 32761259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
    Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
    Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.
    Urschel JD; Vasan H; Blewett CJ
    Am J Surg; 2002 Mar; 183(3):274-9. PubMed ID: 11943125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery.
    Nelson DW; Chang SC; Grunkemeier G; Dehal AN; Lee DY; Fischer TD; DiFronzo LA; O'Connor VV
    Ann Surg Oncol; 2018 Dec; 25(13):4012-4019. PubMed ID: 30229418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant therapy for pancreatic cancer.
    Lowy AM
    J Gastrointest Surg; 2008 Sep; 12(9):1600-8. PubMed ID: 18259825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials.
    Xu XH; Peng XH; Yu P; Xu XY; Cai EH; Guo P; Li K
    Asian Pac J Cancer Prev; 2012; 13(1):103-10. PubMed ID: 22502650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
    Motoi F; Unno M
    Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
    Hackert T; Ulrich A; Büchler MW
    Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
    [No Abstract]   [Full Text] [Related]  

  • 60. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.